| Walgreen Company | (NY: WAG) |
|
USD
|
|
Official Closing Price
/ Updated: /
|
| View: | Quote | Chart | News | SEC Filings |
(WAG) Community Analysis from
Bulls REASONS TO BUY
|
91%
agree
124 votes
|
Good store locations |
|
100%
agree
15 votes
|
Company undervalued |
|
100%
agree
3 votes
|
Under the Radar |
Bears REASONS TO SELL
|
65%
agree
60 votes
|
Unhappy customers AND Staff |
|
50%
agree
20 votes
|
Same boring company |
|
25%
agree
4 votes
|
Net income falls despite increase in Sales |
May 21, 2013
(Stock Blog Hub,
5/2/13)
On Apr 17, we reaffirmed our long-term Neutral recommendation on Walgreen Co. (WAG) following the mixed second-quarter fiscal 2013 results. While the last quarter results reflect a definite...(read more)
(Stock Blog Hub,
3/28/13)
Walgreen Co. (WAG) reported net earnings of $756 million or 79 cents per share in the second quarter of fiscal 2013, higher than the year-ago net earnings of $683 million or 78...(read more)
(The DIV-Net,
10/1/12)
Linked here is a detailed quantitative analysis of Walgreen Co. (WAG). Below are some highlights from the above linked analysis:
Company Description:
Walgreen Co. is the largest U.S. retail drug...(read more)
Walgreen Company (WAG) Company Overview
Walgreens (NYSE:WAG) is a U.S. drug retailer that sells both prescription and non-prescription drugs as well as retail merchandise (cosmetics, convenience foods, photo processing services, seasonal merchandise, etc). In addition to its store offerings, Walgreens provides pharmacy services like prescription fulfillment. The company operates roughly 7,000 retail locations in the U.S.[1]
(Read more at Wikinvest
) What's in this WAG analysis on Wikinvest...
- Company Overview
- Product Classes[3]
- Financial and Operating Metrics
- FY2011 Q1 Earnings Summary
- FY2011 Q2 Earnings Summary
- Trends and Forces
- Walgreens In-Store Brands will Help the Company Push for Higher Profit Margins
- Economic Slowdown Hurts Walgreens
- Medicare Part D and Medicaid
- Health Reform Legislation
- Additional Influential Factors
- When Major Drug Manufacturers Suffer, Retail Pharmacy Generics Prosper
- Competition
